NGNE

Neurogene Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website neurogene.com
Employees(FY) 82
ISIN US64135M1053

Performance

+8.09%

-24.42%

-61.5%

-56.95%

-26.33%

YTD

-44.16%

Profile

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Advanced Technical Analysis

Technical Analysis of NGNE 2025-02-03

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 30 and the Technical Score at 36, both indicating weakness. Although the Oscillators Score at 56 suggests a neutral stance, the overall combined scores imply a cautious outlook for the stock.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NGNE

Stock Rank

Recent News & Updates

2024-06-03 07:30
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program(Business Wire)
2024-06-02 19:30
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program(Businesswire)
2024-05-10 07:30
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates(Business Wire)
2024-05-10 01:54
NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024(Investorplace)
2024-05-09 19:30
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates(Businesswire)
2024-05-09 19:30
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates(Businesswire)
2024-05-07 06:19
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting(Business Wire)
2024-05-06 18:19
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting(Businesswire)
2024-04-22 16:36
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting(Business Wire)
2024-04-22 04:36
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting(Businesswire)
2024-03-20 05:31
Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023(GuruFocus.com)
2024-03-19 06:48
With 32% ownership, Neurogene Inc. (NASDAQ:NGNE) has piqued the interest of institutional investors(Simply Wall St.)
2024-03-18 16:14
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates(Business Wire)
2024-03-18 04:14
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates(Businesswire)
2024-03-04 07:30
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial(Business Wire)
2024-03-03 18:30
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial(Businesswire)
2024-02-29 07:30
Neurogene to Participate in Upcoming Investor Conferences(Business Wire)
2024-02-28 18:30
Neurogene to Participate in Upcoming Investor Conferences(Businesswire)
2024-01-16 07:00
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer(Business Wire)
2024-01-15 18:00
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer(Businesswire)
2024-01-05 07:00
Neurogene Announces Business Update and 2024 Outlook(Business Wire)
2024-01-04 18:00
Neurogene Announces Business Update and 2024 Outlook(Businesswire)
2023-12-19 07:00
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million(Business Wire)
2023-12-18 18:00
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million(Businesswire)

Page 2 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.